Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer Journal Article


Authors: Hampras, S. S.; Sucheston-Campbell, L. E.; Cannioto, R.; Chang-Claude, J.; Modugno, F.; Dörk, T.; Hillemanns, P.; Preus, L.; Knutson, K. L.; Wallace, P. K.; Hong, C. C.; Friel, G.; Davis, W.; Nesline, M.; Pearce, C. L.; Kelemen, L. E.; Goodman, M. T.; Bandera, E. V.; Terry, K. L.; Schoof, N.; Eng, K. H.; Clay, A.; Singh, P. K.; Joseph, J. M.; Aben, K. K. H.; Anton-Culver, H.; Antonenkova, N.; Baker, H.; Bean, Y.; Beckmann, M. W.; Bisogna, M.; Bjorge, L.; Bogdanova, N.; Brinton, L. A.; Brooks-Wilson, A.; Bruinsma, F.; Butzow, R.; Campbell, I. G.; Carty, K.; Cook, L. S.; Cramer, D. W.; Cybulski, C.; Dansonka-Mieszkowska, A.; Dennis, J.; Despierre, E.; Dicks, E.; Doherty, J. A.; du Bois, A.; Dürst, M.; Easton, D.; Eccles, D.; Edwards, R. P.; Ekici, A. B.; Fasching, P. A.; Fridley, B. L.; Gao, Y. T.; Gentry-Maharaj, A.; Giles, G. G.; Glasspool, R.; Gronwald, J.; Harrington, P.; Harter, P.; Hasmad, H. N.; Hein, A.; Heitz, F.; Hildebrandt, M. A. T.; Hogdall, C.; Hogdall, E.; Hosono, S.; Iversen, E. S.; Jakubowska, A.; Jensen, A.; Ji, B. T.; Karlan, B. Y.; Kellar, M.; Kelley, J. L.; Kiemeney, L. A.; Klapdor, R.; Kolomeyevskaya, N.; Krakstad, C.; Kjaer, S. K.; Kruszka, B.; Kupryjanczyk, J.; Lambrechts, D.; Lambrechts, S.; Le, N. D.; Lee, A. W.; Lele, S.; Leminen, A.; Lester, J.; Levine, D. A.; Liang, D.; Lissowska, J.; Liu, S.; Lu, K.; Lubinski, J.; Lundvall, L.; Massuger, L. F. A. G.; Matsuo, K.; McGuire, V.; McLaughlin, J. R.; McNeish, I.; Menon, U.; Moes-Sosnowska, J.; Narod, S. A.; Nedergaard, L.; Nevanlinna, H.; Nickels, S.; Olson, S. H.; Orlow, I.; Weber, R. P.; Paul, J.; Pejovic, T.; Pelttari, L. M.; Perkins, B.; Permuth-Wey, J.; Pike, M. C.; Plisiecka-Halasa, J.; Poole, E. M.; Risch, H. A.; Rossing, M. A.; Rothstein, J. H.; Rudolph, A.; Runnebaum, I. B.; Rzepecka, I. K.; Salvesen, H. B.; Schernhammer, E.; Schmitt, K.; Schwaab, I.; Shu, X. O.; Shvetsov, Y. B.; Siddiqui, N.; Sieh, W.; Song, H.; Southey, M. C.; Tangen, I. L.; Teo, S. H.; Thompson, P. J.; Timorek, A.; Tsai, Y. Y.; Tworoger, S. S.; Tyrer, J.; van Altena, A. M.; Vergote, I.; Vierkant, R. A.; Walsh, C.; Wang-Gohrke, S.; Wentzensen, N.; Whittemore, A. S.; Wicklund, K. G.; Wilkens, L. R.; Wu, A. H.; Wu, X.; Woo, Y. L.; Yang, H.; Zheng, W.; Ziogas, A.; Gayther, S. A.; Ramus, S. J.; Sellers, T. A.; Schildkraut, J. M.; Phelan, C. M.; Berchuck, A.; Chenevix-Trench, G.; Cunningham, J. M.; Pharoah, P. P.; Ness, R. B.; Odunsi, K.; Goode, E. L.; Moysich, K. B.
Article Title: Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer
Abstract: Background: Regulatory T (Treg) cells, a subset of CD4+ T lymphocytes, are mediators of immunosuppression in cancer, and, thus, variants in genes encoding Treg cell immune molecules could be associated with ovarian cancer. Methods: In a population of 15,596 epithelial ovarian cancer (EOC) cases and 23,236 controls, we measured genetic associations of 1,351 SNPs in Treg cell pathway genes with odds of ovarian cancer and tested pathway and gene-level associations, overall and by histotype, for the 25 genes, using the admixture likelihood (AML) method. The most significant single SNP associations were tested for correlation with expression levels in 44 ovarian cancer patients. Results: The most significant global associations for all genes in the pathway were seen in endometrioid (p = 0.082) and clear cell (p = 0.083), with the most significant gene level association seen with TGFBR2 (p = 0.001) and clear cell EOC. Gene associations with histotypes at p < 0.05 included: IL12 (p = 0.005 and p = 0.008, serous and high-grade serous, respectively), IL8RA (p = 0.035, endometrioid and mucinous), LGALS1 (p = 0.03, mucinous), STAT5B (p = 0.022, clear cell), TGFBR1 (p = 0.021 endometrioid) and TGFBR2 (p = 0.017 and p = 0.025, endometrioid and mucinous, respectively). Conclusions: Common inherited gene variation in Treg cell pathways shows some evidence of germline genetic contribution to odds of EOC that varies by histologic subtype and may be associated with mRNA expression of immune-complex receptor in EOC patients.
Keywords: ovarian cancer; biomarkers; genetic variation; immunosuppression; tgfbr2
Journal Title: Oncotarget
Volume: 7
Issue: 43
ISSN: 1949-2553
Publisher: Impact Journals  
Date Published: 2016-10-25
Start Page: 69097
End Page: 69110
Language: English
DOI: 10.18632/oncotarget.10215
PROVIDER: scopus
PUBMED: 27533245
PMCID: PMC5340115
DOI/URL:
Notes: Article -- Export Date: 6 December 2016 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Sara H Olson
    234 Olson
  2. Douglas A Levine
    380 Levine
  3. Irene Orlow
    247 Orlow